AptaBio Therapeutics Inc.

KOSDAQ:A293780 Rapporto sulle azioni

Cap. di mercato: ₩177.1b

AptaBio Therapeutics Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jin Soo

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOno data
Proprietà del CEO19.2%
Durata media del managementNessun dato
Durata media del Consiglio di amministrazioneNessun dato

Aggiornamenti recenti sulla gestione

Recent updates

AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Oct 29
AptaBio Therapeutics (KOSDAQ:293780) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Jul 12
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?

Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Mar 26
Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money

Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Feb 23
Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?

Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

Jan 01
Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth

AMMINISTRATORE DELEGATO

Jin Soo

no data

Mandato

Dr. Soo Jin Lee, Ph.D. serves as Chief Executive Officer of AptaBio Therapeutics Inc. Dr. Lee is highly experienced in drug discovery and management for pharmaceutical research and development. She has ove...